Visible Extractive Spectrophotometric Estimation of Sofosbuvir in Bulk and in Pharmaceutical Formulations

When used in combination with Velpatasvir as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with Ribavirin if associated with decompensated cirrhosis. The optical characteristics such as absorption maxima, Beer's law limits, molar absorptivity and Sandell's sensitivity are presented in Table I. The regression analysis using the method of least squares was made for slope (m), intercept (b) and correlation obtained from different concentrations and the results are summarized in Table I. The reproducibility and precision of the methods are very good as shown by the low values of coefficient of variance (CV). [...]the proposed methods are simple, sensitive, accurate and economical for the routine estimation of Sofosbuvir in bulk and in its formulations. "FDA approves Epclusa for treatment of chronic Hepatitis C virus infection".